Radiopharmaceuticals targeting MC1R are under investigation in patients with advanced melanoma (NCT05655312, NCT05496686).21,25 A phase I clinical trial is currently investigating the safety and efficacy of [212Pb]VMT01, an MC1R-targeting alpha-particle emitting agent, in patients with unresectable or metastatic melanoma.25 The study is designed as a dose-escalation and expansion trial involving up to 52 patients and seeks to determine the maximum tolerated dose of [212Pb]VMT01. The gene discussed is MC1R; the disease is metastatic melanoma.